Newsroom.

(22 April 2025): Recce Pharmaceuticals (ASX:RCE) has received Human Research Ethics Approval (HREC) to enrol up to 20 additional patients with Diabetic Foot Infections in its Phase 2 trial of R327G.

(15 April 2025): Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has passed its final in vivo preclinical safety study before regulatory submission for the upcoming HERACLES clinical trial.

(10 April 2025): Recce Pharmaceuticals (ASX:RCE) has announced a significant capital raise to support Phase 3 topical clinical trials in Indonesia and Australia.

(25 March 2025): Noxopharm (ASX:NOX) has announced an expanded work program for 2025 with its strategic partner, Melbourne’s Hudson Institute of Medical Research.

(20 March 2025): Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced that the US FDA has granted Fast Track Designation to its allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

(20 March 2025): Late-stage immunotherapy company Immutep (ASX:IMM) has announced an upcoming poster presentation for the pivotal TACTI-004 Phase 3 trial.

(18 March 2025): Race Oncology (ASX:RAC) has announced that Bellberry has approved a phase one clinical trial of RC220 bisantrene alone and combined with doxorubicin in patients with solid tumours.

(18 March 2025): Nyrada (ASX:NYR) has commenced recruitment for its phase one clinical trial of its lead drug candidate NYR-BI03.

(18 March 2025): OncoSil Medical (ASX:OSL) has announced the appointment of Shelley Steyn as chief financial officer, effective 5 May.

(13 March 2025): Australian biotechnology company Noxopharm (ASX:NOX) has engaged Doherty Clinical Trials to conduct its upcoming phase 1 HERACLES trial.

(4 March 2025): Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Darren Keamy as its chief financial officer and company secretary starting today.

(27 February 2025): Clinical-stage regenerative medicine company Cambium Bio (ASX:CMB) has announced that the US FDA has approved the protocol for the registration-enabling Phase 3 clinical trials of Elate Ocular for the treatment of moderate to severe dry eye disease.

(25 February 2025): A new whitepaper from On Q Recruitment explores the key findings of its 2024 Salary & Job Market Report, highlighting how salary trends shape Australia’s life sciences industry.

(20 February 2025): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced that the US FDA has granted fast-track designation for 67Cu-SAR-bisPSMA for the treatment of adult patients with a form of prostate cancer.

(18 February 2025): Clinical-stage drug development company Syntara (ASX:SNT) has announced new findings from a subgroup analysis of 14 patients from the placebo-controlled SOLARIA2 trial.

(11 February 2025): Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly to research and develop innovative cancer treatments.

(4 February 2025): AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, has successfully completed an oversubscribed US$112 million Series C financing.

(4 February 2025): Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has successfully passed a set of important preclinical safety tests ahead of the upcoming HERACLES clinical trial.

(23 January 2025): Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial.

(20 December 2024): Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.

(17 December 2024): Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II in humans.

(12 December 2024): Clinical-stage biotechnology company FivepHusion has announced a commercial transaction with the University of Wollongong for an exclusive option over its ResectAssist Drug Delivery Platform.

(12 December 2024): Immutep (ASX:IMM) has announced positive clinical results from Cohort B of the TACTI-003 (KEYNOTEC34) Phase 2b trial.

(10 December 2024): Clinical-stage biotechnology company FivepHusion has announced Human Regulatory Ethics Committee approval for the next clinical trial of Deflexifol to treat solid tumours.

(10 December 2024): Recce Pharmaceuticals (ASX:RCE) has received approval from the Indonesian Drug and Food Regulatory Authority to initiate its registrational Phase 3 clinical trial, which will assess RECCE 327 as a topical gel for treating diabetic foot infections.

(5 December 2024): Race Oncology (ASX:RAC) has announced the submission of the ethics and regulatory package to Bellberry Human Research Ethics Committee for approval of a Phase 1 clinical trial of RC220.

(26 November 2024): Professor David Thomas said, “We are on the cusp of a new era in cancer care. It’s imperative to integrate this approach as mainstream care for all Australians.”

(21 November 2024): Race Oncology (ASX:RAC) says it has completed an FTO-targeted drug discovery program at Monash University’s Fragment Platform.

(14 November 2024): Clinical-stage company Immutep (ASX:IMM) has announced positive data from the investigator-initiated INSIGHT-003 Phase 1 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.

(5 November 2024): Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. 

(5 November 2024): Recce Pharmaceuticals (ASX:RCE) says it is nearing completion of its Phase 2 clinical trial of RECCE 327 Topical Gel (R327G) targeting Acute Bacterial Skin and Skin Structure Infections.

(29 October 2024): Actinogen Medical (ASX:ACW) has announced the appointment of Andrew Udell, a US-based executive, as its chief commercial officer, reporting to CEO Dr Steven Gourlay.

(17 October 2024): CEO James Bonnar said, "We are thrilled to have completed the GLP studies, which have confirmed a favourable safety profile for NYR-BI03, giving us confidence that it will transition well into human studies."

(10 October 2024): Noxopharm (ASX:NOX) has contracted a specialist supplier to manufacture SOF-SKN for the upcoming HERACLES clinical trial.

(3 October 2024): Nyrada (ASX:NYR) has announced positive results from a preclinical rat study evaluating the efficacy of its lead drug candidate, NYR-BI03, in coronary heart disease.

(24 September 2024): Immutep (ASX:IMM) has announced it has received a €2,194,918 (~A$3,6) research and development tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme

(17 September 2024): Immutep (ASX:IMM) has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA.

(10 September 2024): Nyrada (ASX:NYR) has provided an update on the development of its brain injury program with investigative first-in-class neuroprotection treatment, NYR-BI03.

(10 September 2024): Biotron (ASX:BIT) has provided an update on the BIT225-012 Phase 2 clinical trial of its lead antiviral drug BIT225 for treating COVID-19.

(5 September 2024): Noxopharm (ASX:NOX) has announced progress on its Chroma technology platform, encouraging early drug leads with anticancer activity for glioblastoma and leukaemia.

(2 September 2024): Race Oncology (ASX:RAC) has announced that the first phase of the board renewal process, which commenced in 2023, is now complete with a newly appointed board.

(29 August 2024): Contract Research Organisation Novotech has been recognised as a Workplace Gender Equality Agency Employer of Choice for Gender Equality in 2024.

(20 August 2024): Noxopharm (ASX:NOX) has announced its first-in-human trial for SOF-SKN, a novel investigative candidate for autoimmune diseases.

(15 August 2024): Noxopharm (ASX:NOX) has announced new data regarding its CRO-67 preclinical drug for pancreatic cancer.

(15 August 2024): Immutep (ASX:IMM) has announced that the first participant has been successfully dosed in the first-in human Phase 1 trial of IMP761.

(30 July 2024):  Monash University has welcomed Health Minister Mark Butler's $19 million investment in six mRNA research projects via the Medical Research Future Fund.

(30 July 2024): Cochlear (ASX:COH) has announced that Caroline Clarke has been appointed a non-executive director to its board.

(18 July 2024):  Burnet senior research officer Dr Liriye Kurtovic has been awarded a Moderna Global Fellowship to support her research into developing a new malaria vaccine.

(16 July 2024): Rebecca Lee, the managing director of Merck Life Science Australia and New Zealand, confirmed that a breadth of services will be covered, such as fertility tests, in vitro fertilisation treatments, and hormonal treatments.

(16 July 2024): Immutep (ASX:IMM) has announced positive results from the second cohort of its Phase 2b trial involving its eftilagimod alfa in combination with MSD's KEYTRUDA (pembrolizumab).

(2 July 2024): The board of the Sydney-based Viral Vector Manufacturing Facility has appointed Stephen Thompson as its inaugural CEO.

(2 July 2024): Actinogen Medical (ASX:ACW) has announced that following yesterday's final trial patient visit in the UK, it expects top-line results for the XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder to be available in the first half of August.

(27 June 2024): Immutep (ASX:IMM) has announced topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase 2b trial evaluating its eftilagimod alfa in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatment of recurrent and metastatic head and neck squamous cell carcinoma.

(27 June 2024): Actinogen Medical (ASX:ACW) has announced the peer-reviewed publication of its phase 2a biomarker trial entitled 'Plasma pTau181 Predicts Clinical Progression In A Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem for Mild Alzheimer’s Disease' in the 100th edition of the Journal of Alzheimer’s Disease.

(25 June 2024): New South Wales, Queensland, South Australia, Victoria, and Western Australia 2024-25 State budgets reflect evolving economic environment while continuing investments in life sciences infrastructure and commercialisation.

(25 June 2024): A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system’s response to fight cancer, have been identified under Immutep’s collaboration with the world-leading scientists at Cardiff University.

(25 June 2024): Australian clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the dosing of the first patient in the intravenous infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial.

(20 June 2024): Biotron (ASX:BIT) has announced that preliminary data analyses from the BIT225-011 Phase 2 clinical trial of its lead antiviral drug BIT225 indicate that the primary objectives have been met.

(20 June 2024): The company is seeking applications from emerging biopharmaceutical and biotechnology start-ups in Australia and New Zealand for its Advance Biotech Grant Program.

(11 June 2024): Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has updated investors on the PANCOSIL clinical trial.

(6 June 2024): Australia's largest cancer genomics initiative has achieved a significant milestone. Over 5,000 Australians diagnosed with hard-to-treat cancers with minimal treatment options have received referrals for free comprehensive genomic profiling.

(4 June 2024):  Immutep (ASX:IMM) has launched a fully underwritten equity raising of approximately $100 million and a Phase 3 clinical trial collaboration with MSD.

(23 April 2024): Noxopharm CEO Dr Gisela Mautner added, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development."

(18 April 2024):  AusBiotech has outlined two key recommendations in its response to Investment NSW’s Innovation Blueprint consultation: invest in sector maturation, and foster a culture of entrepreneurship.

(18 April  2024):  Immutep Limited (ASX:IMM) has entered into an agreement with the Centre for Human Drug Research (CHDR) in the Netherlands to perform a first-in-human clinical study of IMP761.

(16 April  2024): Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has announced the first treatment utilising the OncoSil device on a patient residing in Turkey.

(16 April  2024): Next Science (ASX:NXS) has announced the publication of a study it says demonstrates the efficacy of XPERIENCE in decreasing periprosthetic joint infection following a Total Knee Arthroplasty.

(4 April  2024): Clinical stage immunooncology company Imugene (ASX:IMU) has received a Notice of Grant from the Chinese Patent Office, following earlier Grants in Japan and South Korea.

(26 March  2024): Cochlear (ASX:COH) has announced that Yasmin Allen AM is resigning from its board as an independent non-executive director.

(14 March 2024): AusBiotech’s Board of Directors welcomes Dell Kingsford Smith, VP, Medical Affairs, Market Access & Government Affairs, Cochlear, as Board Observer.

(7 March  2024): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has shared additional data from its diagnostic Cu-SAR-bisPSMA trial, COBRA.

(5 March  2024): AusBiotech Members are invited to register for a virtual discussion forum to support its industry-led response to Investment NSW’s Innovation Blueprint. 

(15 February 2024): Clarity Pharmaceuticals (ASX:CU6) has announced positive results from its diagnostic 64Cu-SAR-bisPSMA trial, COBRA (NCT05249127).

(15 February 2024): Australian clinical-stage drug development company Syntara (ASX:SNT) has announced a new Phase 2 trial evaluating the combination treatment of its SNT-5505 with chemotherapy in patients with low and intermediate-risk myelodysplastic syndrome.

(13 February 2024): With the announcement of the NSW Women in Life Sciences Luncheon 2024 speakers, industry is encouraged to register for the must-attend event taking place on International Women’s Day, as seats at the table are limited.  

(8 February 2024): Recce Pharmaceuticals (ASX:RCE) has signed a Memorandum of Understanding with Indonesian organisation PT Etana Biotechnologies to accelerate the development of the Australian company's anti-infective portfolio.

(8 February 2024): Cochlear (ASX:COH) has upgraded its earnings guidance following better-than-expected growth in implant revenue for the half year ended December 2023.

(6 February 2024): FivepHusion has announced that a poster of the most recently completed deflexifol clinical trial was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

(14 December 2023): The Australian company said the designation reflects the potential of its EnGeneIC EDV (EnGeneIC Dream Vector) for the treatment of pancreatic ductal adenocarcinoma.

(14 December 2023): Clinical-stage drug development company Syntara (ASX:SNT), formerly Pharmaxis, has commenced dosing in the final cohort of a phase 2 clinical trial studying its pan-LOX inhibitor SNT-5505 in patients with myelofibrosis.

(5 December 2023):  A NSW-focused strategy has been launched by AusBioNSW, to be led together with the newly appointed AusBioNSW Leadership Committee Chair Lis Boyce, Piper Alderman.

(30 November 2023): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the successful completion of the first stage of cohort three of the Phase 2/2a theranostic trial, SECuRE.

(9 November 2023): Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha in combination with paclitaxel has been completed with no safety or tolerability issues.

(9 November 2023): Radiopharmaceuticals company Clarity Pharmaceuticals (ASX:CU6) has announced that 50 patients have been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial, SABRE.

(1 November): Clinical-stage immuno-oncology company Imugene (ASX: IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumour) trial evaluating the safety of novel cancer-killing virus CF33hNIS (VAXINIA) has cleared cohort 4 of the intravenous arm of the monotherapy dose escalation study.

(26 October 2023): Imugene (ASX:IMU) has announced that its CD19 oncolytic virotherapy drug candidate, onCARlytics, has commenced a Phase 1 clinical trial, with the first patient now dosed.

(24 October 2023): Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab).

(17 October 2023): Professor Michelle Simmons, Professor Chris Greening, Professor Glenn King, and Associate Professor Lara Herrero have been recognised for their extraordinary contributions to science at the 2023 Prime Minister’s Science awards in Canberra.

(10 October 2023): David Ranson, executive chairman of FivepHusion, said, “As we pursue late clinical-stage development of our lead drug Deflexifol, augmenting and expanding the diversity and skill set of our Board is paramount to optimally positioning our company for global development activities and commercialisation."

(5 October 2023): The US FDA has granted Orphan Drug Designation status to Noxopharm's (ASX:NOX) CRO-67 preclinical drug candidate for the treatment of pancreatic cancer.

(3 October 2023): Significant changes for Pharmaxis (ASX:PXS) with the company announcing a new name and the sale of the mannitol respiratory business.

(14 September 2023): Immutep (ASX:IMM) has announced the regulatory authorisation of eftilagimod alpha manufactured at commercial 2,000L scale for clinical trials across multiple countries, including Germany, Belgium, Denmark, and the UK.

(12 September 2023): Clinical-stage immuno-oncology company Imugene (ASX:IMU) has announced the grant of a new patent for its PD1-Vaxx clinical drug candidate.

(12 September 2023): BCAL Diagnostics (ASX:BDX) says it has met a major milestone in its development pathway to launching a blood test for breast cancer. 

(7 September 2023): The company said the funds raised will be used to progress its Phase 2 clinical trial program, including completion of the XanaCIDD trial of Xanamem in patients with cognitive impairment associated with depression.

(7 September 2023): FivepHusion has announced that the first patient has commenced treatment as part of the Deflexifol at Relapse Trial.

(31 August 2023): Pharmaxis (ASX:PXS) has announced the publication in the journal Nature Cancer of preclinical results showing pan-Lysyl Oxidase inhibitor PXS-5505 increases survival by 35 per cent compared to chemotherapy treatment alone in the treatment of pancreatic ductal adenocarcinomas.

(29 August 2023): Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the dosing of the first participant at the highest dose level of 12GBq in the third cohort of its theranostic trial evaluating 67Cu SAR-bisPSMA in patients with prostate cancer.

(17 August 2023): Australian company Imugene (ASX:IMU) has agreed with US-based Precision Biosciences to acquire a worldwide exclusive license to its azer-cel allogeneic CD19 CAR-T cell therapy program.

(10  August 2023): Clinical stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced the completion of cohort two and advancement to cohort three in the dose escalation phase of its Phase 1/2 theranostic trial, SECuRE.

(3  August 2023): Australian clinical-stage biotechnology company Immutep (ASX:IMM) says it has received positive scientific advice from the European Medicines Agency for the continued development of its soluble LAG-3 protein and first-in-class MHC Class II agonist, eftilagimod alpha.

(1 August 2023): Allarity Therapeutics and Detsamma Investments, which trades as FivepHusion, have announced a clinical collaboration agreement.

(1 August 2023): The nation’s largest cancer genomics initiative was launched in Sydney last week with the goal of saving or extending the lives of thousands of Australians battling incurable or advanced cancers, including ovarian, pancreatic and sarcomas.

(27 July 2023): Clinical-stage Australian biotech company HaemaLogiX has entered into a co-development agreement with the Peter MacCallum Cancer Centre to conduct the first-in-human Phase 1 trial of its CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma.

(13 July 2023): Pharmaxis (ASX:PXS) has announced details of a final interim analysis of data from ten patients who have completed six months treatment with PXS-5505.

(11 July 2023): Kazia Therapeutics (ASX:KZA) has announced that its lead program, paxalisib, has been awarded Fast Track Designation by the US FDA.

(11 July 2023): Recce Pharmaceuticals (ASX:RCE) has announced that its Phase 1/2 clinical trial evaluating R327 at faster infusion rates has successfully dosed its first cohort of male and female subjects.

(15 June 2023):  FivepHusion said the collaboration is designed to strategically and optimally progress the development and commercialisation of its enhanced chemotherapeutic formulation of deflexifol.

(1 June 2023): Imugene (ASX:IMU) has announced that the first patient has been dosed in the combination cohort of the IMPRINTER trial.

(1 June 2023): Optiscan Imaging (ASX:OIL) has launched an entitlement offer to raise $16.7 million it says will be used to support its strategic portfolio expansion

(30 May 2023): Immutep (ASX:IMM) has announced it has entered into an agreement under which Charles River will conduct a GLP toxicology study for IMP761.

(30 May 2023): Kazia Therapeutics (ASX:KZA) recently attended and participated in the Cancer Moonshot Brain Cancers Forum on Glioblastoma and Diffuse Intrinsic Pontine Glioma at the White House in Washington DC.

(30 May 2023): GreenLight Clinical, a physician-led Clinical Research Organisation and laboratory, has announced that Dr Robert Lin has been appointed its chief executive officer.

(23 May 2023): OncoSil Medical (ASX:OSL) has announced the first patient treatment in Italy with its OncoSil device.

(25 May 2023): Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment for scarring has met its primary safety objective and two secondary biomarker endpoints in patients with established scars.

(18 May 2023):  Immutep (ASX:IMM) has reported positive results from a clinical trial of its LAG-3 immunotherapy in combination with MSD's PBS-listed anti-PD-1 therapy KEYTRUDA (pembrolizumab).

(18 May 2023): Optiscan Imaging (ASX:OIL) has announced the publication of readout results of its oral cancer imaging study conducted by Dr Camile Farah and his team at the Australian Centre for Oral Oncology Research and Education.

(2 May 2023): Immutep (ASX IMM) has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate a new investigator-initiated trial of eftilagimod alpha.

(13 April 2023): Pharmaxis CEO Gary Phillips said, “The agreement with the FDA to expand the patient population in the ongoing Phase 2 study to include those patients currently on a JAK inhibitor is an important step forward in realising the benefits of lysyl oxidase inhibition for all myelofibrosis patients and in maximising the commercial opportunity for PXS‐5505."

(11 April 2023): Immutep (ASX:IMM), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, has announced that Lis Boyce has been appointed as a non-executive director.

(11 April 2023): Recce Pharmaceuticals (ASX:RCE) has announced that the Australian Patent Office has issued notification of intent to grant the first of its new 'Patent Family 4' for its anti-infectives 'Process for Preparation of Biologically Active Copolymer'.

(28 March 2023): Noxopharm (ASX:NOX) has announced the development of a new product candidate based on mRNA technology as part of the company’s Sofra preclinical platform.

(16 March 2023): Optiscan Imaging (ASX:OIL) has announced the interim results of its oral imaging study conducted at the Australian Centre for Oral Oncology Research and Education.

(14 March 2023): Immutep (ASX:IMM) has announced the initiation of the AIPAC-003 clinical trial evaluating its eftilagimod alpha in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer.

(7 March 2023): GreenLight Clinical and Cure Therapeutics have conducted a signing ceremony in Sydney with the two companies looking to collaborate on the evaluation of potential cancer therapy.

(23 February 2023): Noxopharm (ASX:NOX) has announced that research from its inflammation-related Sofra preclinical program will be presented orally at the upcoming 15th International Congress on Systemic Lupus Erythematosus.

(07 February 2023): Australian clinical-stage biotechnology company Immutep (ASX:IMM) has announced that the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with first-line Non-small cell lung cancer.

(07 February 2023): Optiscan Imaging has announced an exclusive collaboration with Canadian-based Prolucid Technologies to develop AI algorithms and telepathology workflows using its confocal laser endomicroscopy technology.

(06 December 2022): Australian company Noxopharm (ASX:NOX) has provided an update on the IONIC Investigator-initiated pilot Phase 1 clinical trial of its lead oncology drug candidate Veyonda.

(01 December 2022): Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple forms of cancer.

(29 November 2022): Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab).

(20 September 2022): Noxopharm (ASX:NOX) has announced the resignation of founder Dr Graham Kelly as a non-executive director in a move it describes as a natural evolution.

(15 September 2022): Noxopharm (ASX:NOX) has announced what it describes as encouraging new preclinical data from its long-term collaboration with UNSW Sydney.

(8 September 2022):  Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that the first patient has been dosed in the nextHERIZON Phase 2 clinical trial.

(6 September 2022):  Recce Pharmaceuticals (ASX:RCE) has announced the appointment of Dr John Prendergast as its executive chairman.

(30 August 2022):  Optiscan Imaging (ASX:OIL) has announced the submission to the US FDA of a pre-market notification (510(k)) application for the InVivage device intended for oral tissue imaging.

(19 July 2022):  Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Mike Tonroe as its chief financial officer.

(23 June 2022): The Victorian Government has granted Noxopharm (ASX:NOX) collaborator Hudson Institute of Medical Research a grant of $1.45 million to fund the joint development program of novel anti-inflammatory compounds.

(7 June 2022):  Immutep (ASX:IMM) has released new data from the phase 2 lung cancer trial evaluating its lead product candidate eftilagimod alpha in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in 114 patients.

(2 June 2022): Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of surgical oncologist Dr Yanghee Woo to its scientific advisory board.

(19 May 2022):  Immutep (ASX:IMM) has announced the appointment of four new members to its Clinical Advisory Board.

(10 May 2022):  Immuno-oncology company Imugene (ASX:IMU) has announced it has received Human Research Ethics Committee approval to commence a Phase 2 clinical trial of its immunotherapy candidate, HER-Vaxx in Australia.

(14 April 2022):  Clinical stage immuno-oncology company Imugene (ASX:IMU) says City of Hope in the US has dosed the first cohort two patient in the Phase I clinical trial of the company's oncolytic virotherapy candidate.

(22 March 2022):  Noxopharm (ASX:NOX) has announced that its lead oncology drug candidate Veyonda has been granted Orphan Drug Designation by the US FDA for its use in the treatment of soft tissue sarcoma.

(1 March 2022): Ms Turnbull rejoins Immutep’s board having previously served as its chair from October 2010 to November 2017.

(1 February 2022): Australian company Pharmaxis (ASX:PXS) has announced that a phase 1c trial of its novel topical drug treatment has commenced dosing in patients with established scars. 

(18 January 2022): Pharmaxis (ASX:PXS) says it welcomes new drug development grants from the federal government awarding NHMRC funding to two research teams to advance work they are conducting with two of the company's discoveries.

(9 December 2021): Synthetic anti-infective company Recce Pharmaceuticals (ASX:RCE) has provided an update on its Phase I/II clinical trial for the treatment of burn wound infections.

(26 October 2021): Noxopharm (ASX:NOX) has received Notices of Allowance from patent offices in Australia and Europe covering the use of idronoxil (the active ingredient in Veyonda) as a chemo-enhancing drug.

(23 September 2021): Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced it has received a notice of grant from the Japanese Patent Office for its application to protect its HER-Vaxx immunotherapy.

(31 August 2021): Pharmaxis (ASX:PXS) has announced that its novel topical drug treatment for scarring has delivered positive phase one clinical trial results and will now advance to the next stage of development in patients

(10 August 2021): Clinical-stage drug development company Noxopharm (ASX:NOX) has announced a formal collaboration with the National Cancer Institute within the US National Institutes of Health in the quest for more effective treatments of brain cancer.

(5 August 2021): Immutep (ASX:IMM) has announced that the first patient has been enrolled and safely dosed in INSIGHT-003 study that includes its LAG-3 investigative immunotherapy.

BiotechDispatch (20 May 2021): Recce Pharmaceuticals (ASX:RCE), a company developing new classes of synthetic anti-infectives, has announced further results for its R327.

BiotechDispatch (4 May 2021): Recce Pharmaceuticals (ASX:RCE) has announced that its RECCE 327 has demonstrated bactericidal activity against all six antibiotic-resistant ESKAPE pathogens, including drug-resistant mutations as well as two additional WHO priority pathogens list.

BiotechDispatch (15 April 2021): Australian company Pharmaxis has sold Russian distribution rights to cystic fibrosis therapy BRONCHITOL (mannitol) and completed a $4.4 million placement to institutional investors.

BiotechDispatch (8 April 2021): Recce Pharmaceuticals (ASX:RCE) has announced that a SAS Category A notification has been made to the TGA by a medical practitioner following the successful treatment of a patient with RECCE 327.

BiotechDispatch (6 April 2021): Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced the lodgement of an international patent application aimed at protecting the use of Veyonda (idronoxil) in blocking the development of septic shock associated with infections.

BiotechDispatch (1 April 2021): Pharmaxis (PSX:ASX) has announced a partnership to launch a world-first clinical trial that aims to stop scars from forming after trauma, particularly following burn injuries.

BiotechDispatch (16 March 2021): Immutep (ASX:IMM), an Australian biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, has announced a second clinical trial collaboration and supply agreement with MSD.

BiotechDispatch (9 March 2021): Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced that its lead investigational candidate Veyonda has been approved to move into its second and final stage of the NOXCOVID-1 clinical trial.

BiotechDispatch (23 February 2021): Australian pharmaceutical company Pharmaxis (ASX:PXS) has enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis

BiotechDispatch (9 February 2021): Pharmaxis (ASX:PXS) has triggered a US$3 million milestone payment after exporting the first shipment of its locally developed and manufactured drug BRONCHITOL (mannitol) to the US.

BiotechDispatch (14 January 2021): Noxopharm (ASX:NOX) has announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

BiotechDispatch (12 January 2021):  Pharmaxis (ASX:PXS) has received a US$7 million milestone payment from its US licensee Chiesi following the recent FDA approval of BRONCHITOL (mannitol) for the treatment of cystic fibrosis.

BiotechDispatch (10 December 2020): Immunotherapy company Immutep (ASX:IMM) has announced what it describes as promising overall survival data from a breast cancer trial of its eftilagimod alpha and that its Chinese partner, EOC Pharma, will commence a new phase two clinical trial in up to 152 patients.

BiotechDispatch (3 November 2020): Pharmaxis has become one of the small number of local life science companies to secure FDA approval of an Australian, developed, discovered and manufactured product.

BiotechDispatch (3 November 2020):  Immutep (ASX:IMM) has announced a new licence and collaboration agreement with Laboratory Corporation of America Holdings that will support the development of immuno-oncology products or services.

BiotechDispatch (27 October 2020):  Immutep (ASX:IMM) has signed an agreement with the University Hospital Pilsen in the Czech Republic that will enable an investigator-initiated randomised phase two clinical trial of its lead product candidate eftilagimod alpha (efti) in hospitalised patients with COVID-19.

BiotechDispatch (1 September 2020): Immutep (ASX:IMM) has announced it and research partner Monash University have received a grant under the ARC‘s Linkage Project scheme to support their research collaboration into LAG-3 for a further three years.

BiotechDispatch (20 August 2020): Sydney-based Pharmaxis (ASX:PXS) says the US FDA has completed a safety review of the company’s Investigational New Drug application for its pan-LOX inhibitor PXS-5505 and given it permission to proceed with a new clinical trial.

BiotechDispatch (9 July 2020): Sydney-based anti-infective company Recce Pharmaceuticals (ASX:RCE) has announced an Antiviral SARS-CoV-2 Screening Program Agreement with CSIRO and the University of Melbourne's Doherty Institute.

BiotechDispatch (30 June 2020): Australian immunotherapy company Immutep (ASX:IMM) has announced it has enrolled and safely dosed the last patient for stage two of Part A of its TACTI-002 Phase 2 trial.

BiotechDispatch (18 June 2020): Noxopharm (ASX:NOX) has announced the commencement of its NOXCOVID clinical program with a planned phase one trial in Europe.

BiotechDispatch (2 June 2020): Noxopharm (ASX: NOX) has updated on its presentation of two sets of clinical trial data relating to the development of NOX66 (Veyonda) as a treatment of end-stage cancer.

BiotechDispatch (2 June 2020): Investors have welcomed new data from Australian biopharmaceutical company Immutep from a trial involving its eftilagimod alpha in combination with MSD's PBS-listed immunotherapy KEYTRUDA (pembrolizumab).

BiotechDispatch (14 May 2020): Noxopharm (ASX:NOX) has announced a $7.9 million capital raise its says will go towards progressing its oncology programs as well as its recent move into infection.

BiotechDispatch (30 April 2020): Noxopharm (ASX:NOX) has released details of the radiographic review of its DARRT-1 clinical study and says it shows a major benefit from a combination of Veyonda and low-dose radiotherapy.

BiotechDispatch (28 April 2020): Australian company Pharmaxis (ASX:PXS) says positive results from phase 1b and long-term toxicity studies of its oral anti‐fibrotic LOX inhibitor PXS‐5505 mean it is now progressing to a phase 2 study for the treatment of the rare bone cancer, myelofibrosis. 

BiotechDispatch (9 April 2020):  Australian company Immutep (ASX:IMM) has announced it has worked with its partner EOC Pharma to review study results and they have confirmed plans to continue advancing Efti in metastatic breast cancer.

BiotechDispatch (27 February 2020): CEO Graham Kelly PhD said, “Bringing Veyonda to market for late-stage prostate cancer remains our commercial imperative. This IND grant for a less common cancer type contributes to that overall commercial objective in several ways."

BiotechDispatch (20 February 2020): The Sydney-based biotechnology Immutep (ASX:IMM) company has released new positive data from a trial involving its immunotherapy in combination with MSD's KEYTRUDA (pembrolizumab).

BiotechDispatch (3 December 2019): Australian company Noxopharm (ASX:NOX) has reported positive end-of-study data from its DARRT-1 Phase 1b trial of Veyonda.

BiotechDispatch (21 November 2019): Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, to its newly formed oncolytic virotherapy Scientific Advisory Board.

BiotechDispatch (22 October 2019): Sydney-based Noxopharm (ASX:NOX) has updated on interim data from the DARRT-1 study where Veyonda is being tested in patients with prostate cancer which is late-stage, progressive and metastatic.

BiotechDispatch (17 October 2019): Immutep (ASX:IMM) has announced "mature positive efficacy" data from its TACTI-mel Phase 1 clinical study combining its lead product candidate, eftilagimod alpha, with MSD's KEYTRUDA (pembrolizumab) in metastatic melanoma.

BiotechDispatch (3 October 2019): Noxopharm (ASX:NOX) has provided further information on the upcoming release of clinical data concerning its lead drug candidate, Veyonda, saying it "now sees an important and exciting story emerging".

BiotechDispatch (24 September 2019): GSK has paid Australian immunotherapy company Immutep (ASX:IMM) a $7.4 million milestone payment after the first patient was dosed in the phase 2 study of GSK2831781 in ulcerative colitis.

BiotechDispatch (17 September 2019): Noxopharm (ASX:NOX) has announced that scientific abstracts on interim data relating to its DARRT-1 prostate cancer treatment study have been accepted for inclusion in two major oncology conferences.

BiotechDispatch (22 August 2019): Noxopharm (ASX:NOX) has provided an update on results from a series of proof-of-principle experiments in mice that are exploring the interaction between Veyonda and radiotherapy in a novel treatment regimen known as DARRT.

BiotechDispatch (16 July 2019): Australian immuno-oncology company Imugene (ASX:IMU) has boosted its investigational portfolio through the acquisition of local counterpart Vaxinia with global rights to a new oncolytic virus technology.

BiotechDispatch (6 June 2019): Sydney-based Immutep (ASX:IMM) has announced that the first patient in the INSIGHT-004 phase 1 clinical trial has been enrolled in Germany and has received the first dose of treatment.

BiotechDispatch (9 May 2019):  Sydney-based Pharmaxis (ASX:PXS) has announced its US licensee Chiesi has received a positive recommendation from a committee advising the US FDA on the use of BRONCHITOL for adult cystic fibrosis patients.

BiotechDispatch (2 April 2019): Imugene (ASX:IMU) has presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta.

BiotechDispatch (7 March 2019): Immutep (ASX:IMM) has announced more data from its ongoing TACTI-mel phase 1 clinical study of its lead product candidate, eftilagimod alpha ('efti' or 'IMP321'), and confirmed the first patient has been dosed in a new phase 2 study, TACTI-002.

BiotechDispatch (28 February 2019): Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has announced Professor Ursula Wiedermann will present on the HER-Vaxx cancer vaccine at the American Association for Cancer Research 2019 Annual Meeting.

BiotechDispatch (25 September 2018): A new collaboration for Immutep (ASX:IMM) with the Sydney-headquartered company announcing a clinical trial collaboration and supply agreement with Merck and Pfizer.

BiotechDispatch (15 March 2018): Immutep (ASX:IMM) has entered a clinical trial collaboration and supply agreement to evaluate the combination of its lead immunotherapy product candidate, eftilagimod alpha ('efti' or 'IMP321'), with MSD's anti-PD-1 therapy KEYTRUDA (pembrolizumab)

BiotechDispatch (5 September 2017): Immuno-oncology company Imugene (ASX:IMU) has announced it has commenced first patient dosing of the Phase 1b/2 clinical study of its HER-Vaxx immunotherapy in gastric cancer.